



**ICNIRP 7th International NIR Workshop**  
Edinburgh, United Kingdom, 9-11 May 2012



# Mobile phones and cancer – what has epidemiology found

**Maria Feychting**

ICNIRP MEMBER

Institute of Environmental Medicine,  
Karolinska Institutet, Stockholm, Sweden



## Studies of mobile phones and cancer

- Focus has been on tumors in the head and neck region
- Mostly brain tumors
  - Glioma, meningioma, acoustic neuroma
- A few studies on parotid gland tumors
- Single studies on uveal melanoma, lymphoma, other tumors



# Brain tumors

- ~15 published studies available on brain tumors and mobile phone use, and slightly fewer on acoustic neuroma
  
- Four groups of studies:
  - Early US-studies
    - Short duration of use
  - Hardell et al.: 3 studies from Sweden
  - Interphone studies: international collaborative studies performed in 13 countries with a common protocol
  - Nordic registry based studies (subscriber data)




# Methodological issues – exposure assessment

- Register based exposure information
  - Non-differential exposure misclassification
    - The subscriber is not necessarily the user of the phone
    - Corporate users difficult to identify
- Self-reported exposure
  - Non-differential exposure misclassification – difficult to remember mobile phone use many years in the past
    - Heavy users tend to overestimate mobile phone use and light users tend to underestimate
    - Can lead to underestimated effects
  - Recall bias
    - Glioma cases overestimate exposure in distant past – can lead to overestimated risk estimates



# Interphone validation study

Ratio of self-reported to registered cumulative hours of phone use





# Methodological issues – selection bias

Non-participation – potential selection bias


→ Mobile phone users more likely to participate

Prevalence of ever mobile phone use in Interphone:


	Refusers	Participants
Controls	56%	69%
Cases	50%	66%

- Leads to underestimation of risk estimates by approx. 10%

# Time since first use, regardless of amount of use: Glioma and mobile phone use, **short** latency period (~ <5 years)



# All studies: Glioma and mobile phone use, **long** induction period, $\sim \geq 10$ years







# Danish mobile phone subscribers cohort

## ■ Results for glioma:

→ **First analysis** (i.e. short-term use): RR=0.94 (0.72-1.20)  
(Johansen 2001)

→ **Update** (short to intermediate-term use): RR=1.01 (0.89-1.14)  
(Schuz 2006)

5-9 years: RR=0.96 (0.84-1.09)

10+ years: RR=0.66 (0.44-0.95)

→ **Second update** (long-term, use)

(Frei et al 2011) 10-12 years: RR=1.06 (0.85-1.34)

≥13 years: RR=0.98 (0.70-1.36)

Incidence trends strongly support absence of short- and intermediate-term effect



# Exposure misclassification, Danish cohort study


Assume that the true relative risk is 2.5



Adding 300,000 subscribers to unexposed results in a RR of 2.23




## Amount of use Interphone, glioma: Cumulative number of calls






## Interphone results, glioma: Cumulative call duration





## Interphone results acoustic neuroma: Cumulative hours of use





## Comments

- Does the increased risk of glioma in the most extreme usage category, >1640 h, reflect causality?
  - There are persons in this category who reports highly implausible call times, more cases than controls
    - e.g. more than 12 hours per day, everyday during many years
  - Validation study of self reported hours of use found that cases overestimate their use more for distant periods than controls
  - No increased risk in relation to cumulative number of calls
    - High correlation between number of calls and duration of calls when analysed in independent sample (Spearman= 0.94, Swedish COSMOS, unpublished data)
  - No dose-response: No risk increase in first nine exposure categories – elevated risk only in the most extreme category




## Laterality of phone use vs tumor

- For causality one would expect
  - For short term use, short duration of use, few phone calls: Risk should be the same as for unexposed subjects, i.e. estimates close to unity for both ipsi- and contralateral use
  - For long term use, long duration, many calls: Increased risk on same side; for opposite side, risk should be the same as for unexposed subjects, i.e. close to unity
  
- **Interphone found:** Higher risk estimates for mobile phone use on the same side as the tumor in **virtually all** exposure categories
  - Often strong protective effect on opposite side of the head
  - Highest ratio of ipsi- to contralateral use among subjects with less than 2 years of mobile phone use and shortest duration of calls
  - **Indicates recall bias when reporting side of use**




## Lobe specific results Interphone: Ever regular mobile phone use







## Lobe specific results Interphone: $\geq 1640$ h of cumulative use



No other study reports higher risk for glioma in the temporal lobe



## **Localization of the tumor in the brain; case-case analyses in 7 countries**

- RF from mobile phone highly localized – most of the exposure absorbed within a few centimeters
- Hypothesis: gliomas in mobile phone users are located closer to the exposure source (i.e. position of the handset) than gliomas in non-users
- Case-case analyses avoids selection bias
  - Included 888 glioma cases
- **Results: glioma in mobile phone users were not preferentially located in highly exposed areas of the brain**

Larjavaara et al. 2011, AJE



## Cardis et al., 2011, estimate of RF energy

Results for top quintile	Complete data	Tumor centre by neurorad. or estimated	Tumor centre by neuroradiologist
Hour of use	<b>1.17 (0.88-1.56)</b>	1.25 (0.88-1.77)	1.72 (1.07-2.77)
RF energy		1.35 (0.96-1.90)	1.66 (1.03-2.67)
RF energy excl. information on side of head		<b>1.21 (0.87-1.68)</b>	Not reported

- If RF exposure was causally related to glioma:
  - Stronger risk estimates would have been expected based on estimated RF energy, than on simply self reported hours of use
    - Almost identical risk estimates when removing info on side of head
- Estimated RF energy seem to rely heavily on self-reported hours of use and side of phone use, both prone to recall bias




## Incidence trends – glioma

- No increased incidence in age-groups where mobile phone use have been prevalent
    - Studies available from Australia (including 2008), the Nordic countries (including 2008), the UK (including 2007), the US (including 2008), Sweden (including 2009)
  
  - Deltour et al., 2012, consistency check comparing the stable incidence trends with results from some case-control studies:
    - **100% probability that**
      - a RR of 2.0 with up to 15 years induction period
      - a RR of 1.5 with up to 10 years induction period
      - a RR of 1.2 with up to 5 years induction period
      - 98% probability that a RR of 1.5 among heavy users ( $\geq 1640$  h)
- would be seen in incidence trends in the Nordic countries**




# UK: Age specific brain cancer incidence trends 1998-2007, de Vocht et al., Bioelectromagnetics, 2011





## Observed and projected incidence of glioma in the US based on results from case-control studies



Little M P et al. BMJ 2012;344:bmj.e1147



## Mobile phone use and childhood brain tumors

- So far only one study published (Aydin et al. JNCI 2011)
  - Risk estimates slightly above unity, but non-significant
  - No exposure-response relationship in terms of amount of mobile phone use or localization of the brain tumor
  
- Brain tumor incidence trends in children and adolescents remain stable since the introduction of mobile phones
  - Published data from Australia, Nordic countries, Sweden, UK, US



# Conclusions

- So far little evidence that mobile phone use affect brain tumor risk
- Incidence trends are not compatible with the few observed risk increases
- However, some uncertainties remain:
  - Still short induction period – up to around 15 years
  - Need to follow-up on the results for heaviest users
- Can only be done with prospective design combining self-reported and registered mobile phone use
  - Must minimize recall bias and non-differential exposure misclassification, as well as selection bias
- Follow brain tumor incidence trends in high quality registers